CXCL14 and neoplasm: In summary, our study highlights the role of the differentiated stage from transitional CXCL14+ myCAFs to invasiveness‐associated myCAFs in driving tumor progression and therapy resistance in LUAD, positioning Filgotinib as a promising targeted therapy for this process.